Most Read Articles
Pearl Toh, 13 Apr 2018
Impaired endothelial-dependent microvascular reactivity appears to be predictive of albuminuria progression in Asian patients with type 2 diabetes (T2D) who have normal urine albumin levels at baseline, but not in those with microalbuminuria, a prospective longitudinal cohort study suggests.
30 May 2016
Good glycaemic control and minimizing CV risk factors are the cornerstones of T2D management. Empagliflozin, a SGLT2 inhibitor, has a unique mechanism of action that not only lowers plasma glucose but also other CV risk factors. The EMPA-REG OUTCOME® trial explored the CV benefits of this drug, and a panel of eminent speakers gathered recently to present the implications of this study and empagliflozin on clinical practice.
Stephen Padilla, 13 Apr 2018
The use of dipeptidyl peptidase-4 inhibitors may heighten the risk of inflammatory bowel disease (IBD) in patients with type 2 diabetes (T2D), according to a recent study.

Current Trends in Diabetic Hypertension, Chronic Urticaria and Fatty Liver Disease

25 Aug 2015
At the Northern Pharmacists Convention cum 48th Malaysian Pharmaceutical Society Seminar 2015 held recently at Bayview Beach Hotel, Penang, Sanofi invited three distinguished speakers – Dr Khaw Chong Hui, Dr Lo Kang Shang Chit, and Professor Dr Karl-Josef Gundermann – to speak on the importance of renal protection in managing diabetic hypertension, the use of antihistamines in managing chronic urticaria (CU), and the role of essential phospholipids (EPL) in fatty liver diseases, respectively.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 13 Apr 2018
Impaired endothelial-dependent microvascular reactivity appears to be predictive of albuminuria progression in Asian patients with type 2 diabetes (T2D) who have normal urine albumin levels at baseline, but not in those with microalbuminuria, a prospective longitudinal cohort study suggests.
30 May 2016
Good glycaemic control and minimizing CV risk factors are the cornerstones of T2D management. Empagliflozin, a SGLT2 inhibitor, has a unique mechanism of action that not only lowers plasma glucose but also other CV risk factors. The EMPA-REG OUTCOME® trial explored the CV benefits of this drug, and a panel of eminent speakers gathered recently to present the implications of this study and empagliflozin on clinical practice.
Stephen Padilla, 13 Apr 2018
The use of dipeptidyl peptidase-4 inhibitors may heighten the risk of inflammatory bowel disease (IBD) in patients with type 2 diabetes (T2D), according to a recent study.